Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors

Cancer Research

Volumn 60, Issue 3, 2000, Pages 685-692

  Willimsky, Gerald ^a   Blankenstein, Thomas ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; INTERLEUKIN 7;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; CYTOTOXIC T LYMPHOCYTE; EMBRYO; FEMALE; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD80; BETA-GALACTOSIDASE; GENE TRANSFER TECHNIQUES; GRAFT REJECTION; HUMANS; INTERLEUKIN-7; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033968404     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Schreiber, H. Tumor Immunology, 3rd ed., pp. 1143-1178. New York: Raven Press, Ltd., 1993.
2. Foley, E. J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res., 13: 835-837, 1953.
3. Gross, L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res., 3: 326-333, 1943.
4. Prehn, R. T., and Main, J. M. Immunity to methylcholanthrene-induced sarcomas. J. Nail. Cancer Inst., 18: 769-778, 1957.
5. Basombrio, M. A., and Prehn, R. T. Studies on the basis for diversity and time of appearance of antigens in chemically induced tumors. Natl. Cancer Inst. Monogr., 35: 117-124, 1972.
6. Klein, G. Rejection antigens in chemically induced tumors. Proc. Natl. Acad. Sci. USA, 94: 5991-5992, 1997.
7. Boon, T., Coulie, P. G., and Van den Eynde, B. Tumor antigens recognized by T cells. Immunol. Today, 18: 267-268, 1997.
8. Melief, C. J., Offringa, R., Toes, R. E., and Kast, W. M. Peptide-based cancer vaccines. Curr. Opin. Immunol., 8: 651-657, 1996.
9. Steinman, R. M. Dendritic cells and immune-based therapies. Exp. Hematol., 24: 859-862, 1996.
10. Restifo, N. P. The new vaccines: building viruses that elicit antitumor immunity. Curr. Opin. Immunol., 8: 658-663, 1996.
11. Blankenstein, T., Cayeux, S., and Qin, Z. Genetic approaches to cancer immunotherapy. Rev. Physiol. Biochem. Pharmacol., 129: 1-49, 1996.
12. Horiguchi, S., Petersson, M., Nakazawa, T., Kanda, M., Zea, A. H., Ochoa, A. C., and Kiessling, R. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res., 59: 2950-2956, 1999.
13. Singh, S., Ross, S. R., Acena, M., Rowley, D. A., and Schreiber, H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med., 175: 139-146, 1992.
14. Yang, G., Mizuno, M. T., Hellström, K. E., and Chen, L. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. J. Immunol., 158: 851-858, 1997.
15. Kündig, T. M., Bachmann, M. F., DiPaolo, C., Simard, J. J., Battegay, M., Lother, H., Gessner, A., Kuhlcke, K., Ohashi, P. S., Hengartner, H., and Zinkernagel, R. M. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science (Washington DC), 268: 1343-1347, 1995.
16. Ganss, R., and Hanahan, D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res., 58: 4673-4681, 1998.
17. Klein, G., Sjoegren, H. O., Klein, E., and Hellström, E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochtonous host. Cancer Res., 20: 1561-1572, 1960.
18. Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A., and Schreiber, H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med., 186: 229-238, 1997.
19. Pützer, B. M., Hitt, M., Muller, W. J., Emtage, P., Gauldie, J., and Graham, F. L. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA, 94: 10889-10894, 1997.
20. Emtage, P. C., Wan, Y., Bramson, J. L., Graham, F. L., and Gauldie, J. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J. Immunol., 160: 2531-2538, 1998.
21. Cavallo, F., Di, P. F., Giovarelli, M., Gulino, A., Vacca, A., Stoppacciaro, A., Forni, M., Modesti, A., and Forni, G. Protective and curative potential of vaccination with interleukin-2- gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res., 53: 5067-5070, 1993.
22. Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
23. Crystal, R. G. Transfer of genes to humans: early lessons and obstacles to success. Science (Washington DC), 270: 404-410, 1995.
24. Cayeux, S., Beck, C., Aicher, A., Dörken, B., and Blankenstein, T. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol., 25: 2325-2331, 1995.
25. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
26. Huang, A. Y., Bruce, A. T., Pardoll, D. M., and Levitsky, H. I. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med., 183: 769-776, 1996.
27. Cayeux, S., Richter, G., Noffz, G., Dörken, B., and Blankenstein, T. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol., 158: 2834-2841, 1997.
28. Hock, H., Dorsch, M., Diamantstein, T., and Blankenstein, T. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J. Exp. Med., 174: 1291-1298, 1991.
29. Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA, 91: 8802-8806, 1994.
30. McGrory, W. J., Bautista, D. S., and Graham, F. L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology, 163: 614-617, 1988.
31. Adesanya, M. R., Redman, R. S., Baum, B. J., and O'Connell, B. C. Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. Hum. Gene Ther., 7: 1085-1093, 1996.
32. Graham, F. L., and Prevec, L. Methods for construction of adenovirus vectors. Mol. Biotechnol., 3: 207-220, 1995.
33. Nanni, P., de Giovanni, C., Lollini, P. L., Nicoletti, G., and Prodi, G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis, 1: 373-380, 1983.
34. Corbett, T. H., Griswold, D. J., Roberts, B. J., Peckham, J. C., and Schabel, F. J. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res., 35: 2434-2439, 1975.
35. Aicher, A., Westermann, J., Cayeux, S., Willimsky, G., Daemen, K., Blankenstein, T., Uckert, W., Dörken, B., and Pezzutto, A. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells. Exp. Hematol., 25: 39-44, 1997.
36. Kiessling, R., Petranyi, G., Klein, G., and Wigzel, H. Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line. Int. J. Cancer. 15: 933-940, 1975.
37. Park, L. S., Friend, D. J., Schmierer, A. E., Dower, S. K., and Namen, A. E. Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7-dependent cell line. J. Exp. Med., 171: 1073-1089, 1990.
38. Bhisey, R. A., Ramchandani, A. G., Iyengar, B., Borges, A., and Sirsat, S. M. 12-O-Tetradecanoylphorbol-13-acetate-induced amplification of mesenchymal tumorigenesis in the mouse skin. J. Cancer Res. Clin. Oncol., 105: 48-54, 1983.
39. Hock, H., Dorsch, M., Kunzendorf, U., Qin, Z., Diamantstein, T., and Blankenstein, T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc. Natl. Acad. Sci. USA, 90: 2774-2778, 1993.
40. Blankenstein, T., Qin, Z., Überla, K., Müller, W., Rosen, H., Volk, H. D., and Diamantstein, T. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J. Exp. Med., 173: 1047-1052, 1991.
41. Gavin, M. A., Gilbert, M. J., Riddell, S. R., Greenberg, P. D., and Bevan, M. J. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J. Immunol., 151: 3971-3980, 1993.
42. Jain, R. K., and Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res., 48: 7022-7032, 1988.
43. Jooss, K., Yang, Y., Fisher, K. J., and Wilson, J. M. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol., 72: 4212-4223, 1998.
44. Yang, Y., Haecker, S. E., Su, Q., and Wilson, J. M. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum. Mol. Genet., 5: 1703-1712, 1996.
45. Hock, H., Dorsch, M., Kunzendorf, U., Uberla, K., Qin, Z., Diamantstein, T., and Blankenstein, T. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectively not superior to a classical adjuvant. Cancer Res., 53: 714-716, 1993.
46. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., and Pardoll, D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Washington DC), 254: 713-716, 1991.
47. Vermorken, J. B., Claessen, A. M., van, T. H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J., Bloemena, E., Ransom, J. H., Hanna, M. J., and Pinedo, H. M. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet, 353: 345-350, 1999.
48. Kass, E. A., Falck, P. E., Elfenbein, D. H., Alvira, M., Buttrick, P. M., and Leinwand, L. A. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther., 1: 395-402, 1994.
49. Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., and Verma, I. M. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA, 92: 1401-1405, 1995.
50. Barr, D., Tubb, J., Ferguson, D., Scaria, A., Lieber, A., Wilson, C., Perkins, J., and Kay, M. A. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther., 2: 151-155, 1995.
51. Johnston, J. V., Malacko, A. R., Mizuno, M. T., McGowan, P., Hellström, I., Hellström, K. E., Marquardt, H., and Chen, L. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med., 183: 791-800, 1996.
52. Schoenberger, S. P., Jonges, L. E., Mooijaart, R. J., Hartgers, F., Toes, R. E., Kast, W. M., Melief, C. J., and Offringa, R. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. Cancer Res., 58: 3094-3100, 1998.
53. Wu, N. Z., Klitzman, B., Dodge, R., and Dewhirst, M. W. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res., 52: 4265-4268, 1992.
54. Limmer, A., Sacher, T., Alferink, J., Kretschmar, M., Schonrich, G., Nichterlein, T., Arnold, B., and Hämmerling, G. J. Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur. J. Immunol., 28: 2395-2406, 1998.
55. Qin, Z., Richter, G., Schüler, T., Ibe, S., Cao, X., and Blankenstein, T. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med., 4: 627-630, 1998.
56. Toes, R. E., Ossendorp, F., Offringa, R., and Melief, C. J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med., 189: 753-756, 1999
57. North, R. J., and Havell, E. A. The antitumor function of tumor necrosis factor (TNF). II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J. Exp. Med., 167: 1086-1099, 1988.
58. Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall, F. K., Odermatt, B., Hanahan, D., Zinkernagel, R. M., and Ohashi, P. S. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med., 186: 645-653, 1997.